Compare · MOLN vs NBIX
MOLN vs NBIX
Side-by-side comparison of Molecular Partners AG (MOLN) and Neurocrine Biosciences Inc. (NBIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MOLN and NBIX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- NBIX is the larger of the two at $15.85B, about 158.3x MOLN ($100.2M).
- NBIX has been more active in the news (12 items in the past 4 weeks vs 5 for MOLN).
- NBIX has more recent analyst coverage (25 ratings vs 5 for MOLN).
- Company
- Molecular Partners AG
- Neurocrine Biosciences Inc.
- Price
- -
- -
- Market cap
- $100.2M
- $15.85B
- 1M return
- -
- +10.75%
- 1Y return
- -
- +12.68%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 1996
- News (4w)
- 5
- 12
- Recent ratings
- 5
- 25
Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Latest MOLN
- Molecular Partners to Present at Inaugural UBS Global Biopharma Conference
- Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026
- Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
- SEC Form 6-K filed by Molecular Partners AG
- Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
- Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
- SEC Form 6-K filed by Molecular Partners AG
- Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
- SEC Form 6-K filed by Molecular Partners AG
- Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
Latest NBIX
- Director Gary A Lyons exercised 15,000 shares at a strike of $53.64 and sold $2,473,030 worth of shares (15,000 units at $164.87) as part of a pre-agreed trading plan, increasing direct ownership by 3% to 126,241 units (SEC Form 4)
- Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
- Chief Medical Officer Roberts Eiry was granted 8,314 stock options and was granted 1,506 restricted stock units (SEC Form 4)
- Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
- Director Morrow George J exercised 15,000 shares at a strike of $53.64 and sold $2,335,982 worth of shares (15,000 units at $155.73) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Gano Kyle converted options into 614 shares and covered exercise/tax liability with 332 shares, increasing direct ownership by 0.18% to 155,010 units (SEC Form 4) to satisfy withholding obligation
- Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- SEC Form 10-Q filed by Neurocrine Biosciences Inc.
- Neurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits